New immune booster FL115 tested in patients with advanced cancers

NCT ID NCT06130722

Completed Disease control Sponsor: Suzhou Forlong Biotechnology Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a new drug called FL115 in 18 adults with advanced solid tumors that had stopped responding to standard treatments. FL115 is designed to strengthen the body's immune cells to fight cancer. The main goal was to check safety and find the right dose, while also looking for any signs that the drug might shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FL115 (a lab-made protein that boosts immune cells)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is a very early, small Phase 1 trial with only 18 participants. The main goal is safety, not effectiveness, and many early-stage drugs fail to show benefit in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED / METASTATIC SOLID TUMORS

Contacts and locations

Locations

Gabriel Cancer Center

Canton, Ohio, 44718, United States
HOAG Memorial Hospital Presbyterian

Newport Beach, California, 92663, United States
Moores Cancer Center at UCSD Health

San Diego, California, 92037, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.